# Assessment of the Antiviral Effect of Atorvastatin on Hepatitis C Virus

> **NCT00403533** · PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 10 (—)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** 20 mg of atorvastatin daily

## Key facts

- **NCT ID:** NCT00403533
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** —
- **Final completion:** 2006-07
- **Target enrollment:** 10 (—)
- **Last updated:** 2006-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00403533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00403533, "Assessment of the Antiviral Effect of Atorvastatin on Hepatitis C Virus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00403533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*